Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects

Abstract Vutiglabridin, which affects the pharmacokinetics (PKs) of food, is currently under clinical development for the treatment of obesity. This study aimed to evaluate the effects of low‐ and high‐fat meals on PKs of vutiglabridin in healthy male subjects. A randomized, open‐label, single‐dose,...

Full description

Saved in:
Bibliographic Details
Main Authors: Heejae Won (Author), Deok Yong Yoon (Author), Sangmi Lee (Author), Joo‐Youn Cho (Author), Jaeseong Oh (Author), In‐Jin Jang (Author), Sang‐Ku Yoo (Author), Kyung‐Sang Yu (Author)
Format: Book
Published: Wiley, 2024-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_264b145fc6ce4606b5e8e24ef5de711e
042 |a dc 
100 1 0 |a Heejae Won  |e author 
700 1 0 |a Deok Yong Yoon  |e author 
700 1 0 |a Sangmi Lee  |e author 
700 1 0 |a Joo‐Youn Cho  |e author 
700 1 0 |a Jaeseong Oh  |e author 
700 1 0 |a In‐Jin Jang  |e author 
700 1 0 |a Sang‐Ku Yoo  |e author 
700 1 0 |a Kyung‐Sang Yu  |e author 
245 0 0 |a Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects 
260 |b Wiley,   |c 2024-03-01T00:00:00Z. 
500 |a 1752-8062 
500 |a 1752-8054 
500 |a 10.1111/cts.13744 
520 |a Abstract Vutiglabridin, which affects the pharmacokinetics (PKs) of food, is currently under clinical development for the treatment of obesity. This study aimed to evaluate the effects of low‐ and high‐fat meals on PKs of vutiglabridin in healthy male subjects. A randomized, open‐label, single‐dose, three‐period, six‐sequence crossover study was conducted. The subjects received a single oral dose of vutiglabridin 480 mg in a fasted state, 30 min after the intake of a low‐fat meal (total 500-600 kcal, fat content 100-125 kcal) and high‐fat meal (total 800-1000 kcal, fat content 500-600 kcal), with a 21‐day washout period. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for maximum plasma concentration (Cmax) and area under the plasma concentration‐time curve to the last measurable timepoint (AUClast) were calculated. After intake of low‐ and high‐fat meals, systemic exposure to vutiglabridin was increased, and the time to reach Cmax (Tmax) was delayed compared to that in the fasted state. The GMRs (90% CIs) of low‐fat meal to fasted state for Cmax and AUClast were 2.14 (1.76-2.60) and 2.15 (1.92-2.42), respectively, and those of high‐fat meal to fasted state were 3.07 (2.53-3.72) and 3.00 (2.67-3.37), respectively. The median Tmax was delayed by 1.5 h in both fed states compared with that in the fasted state. The study drug was well‐tolerated after administration in both the fed and fasted states. Food ingestion substantially increased the extent of oral vutiglabridin absorption in healthy subjects, and this enhancement increased with the fat content of the meal. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024) 
787 0 |n https://doi.org/10.1111/cts.13744 
787 0 |n https://doaj.org/toc/1752-8054 
787 0 |n https://doaj.org/toc/1752-8062 
856 4 1 |u https://doaj.org/article/264b145fc6ce4606b5e8e24ef5de711e  |z Connect to this object online.